Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04902235
Other study ID # IIBSP-OXI-2020-101
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date July 6, 2021
Est. completion date May 1, 2023

Study information

Verified date March 2022
Source Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Oxytocin (OT) is a hypothalamic peptide that enters the peripheral circulation via the posterior pituitary gland. OT plays a key role in regulating appetite, psychopathology, prosocial behavior and sexual function. Hypopituitarism is associated with increased obesity, increased psychopathology, sexual and prosocial dysfunction despite appropriate hormone replacement. A few studies suggest the existence of a possible OT deficient state in hypopituitarism. In animal models, corticorelin hormone (CRH) has shown to increase OT release. This study is designed to evaluate oxytocin values after administration of CRH in adults (healthy volunteers and patients with hypopituitarism). The investigators hypothesize that OT response will be blunted following CRH in patients with hypopituitarism compared to healthy controls.


Description:

This research is focused on two groups of participants: healthy controls (HC) and hypopituitary patients (HYPO) with at least one symptom of hypothalamic damage, presumably at highest risk for OT deficiency. The aim is to improve knowledge on the physiology and patho-physiology of endogenous OT secretion in hypopituitary patients compared to healthy controls using a randomized, single-blind, crossover assignment (CRH vs placebo), placebo-control design. Clinical implications of secretory OT dynamics and release under different stimuli using validated questionnaires to evaluate psychopathology, socio-emotional functioning, disordered eating behavior, impaired quality of life and sexual dysfunction, will be also evaluated.


Recruitment information / eligibility

Status Completed
Enrollment 52
Est. completion date May 1, 2023
Est. primary completion date April 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Patients with hypopituitarism (HYPO) (>1 pituitary hormone deficiency) and stable hormone replacement for the prior three months - At least one clinical sign of hypothalamic damage - Female participants will be done in the early to midfollicular phase Exclusion Criteria: - uncorrected hormone deficiency - creatinine >1.5mg/dL - alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5x upper limit of normal - hematocrit less than 30% - suicidality or active psychosis - participation in a trial with investigational drugs within 30 days - using a high glucocorticoid dose - vigorous physical exercise - alcohol intake within 24 hours before the study participation - evidence of any acute illness or any illness that the Investigator determines could interfere with study participation or safety - pregnancy or breastfeeding for last 8 weeks - known allergies towards CRH - patients refusing or unable to give written informed consent - Additionally for healthy controls: the presence of brain or pituitary tumor, radiation involving the hypothalamus or pituitary, history of hypopituitarism or receiving testosterone or glucocorticoids esters.

Study Design


Intervention

Drug:
Experimental: CRH administration
CRH at 1.0 µg/kg/body weight will be injected intravenously as a bolus over 30 seconds and samples will be collected over 2 hours (15 (T15), 30 (T30), 45 (T45), 60 (T60'), 90 (T90) and 120 (T120) minutes) after CRH:placebo administration to assess OT secretory patterns
Control: Placebo administration
Sodium Chloride 0.9% will be administered intravenously as a bolus over 30 seconds at equivalent volume than CRH administration (1.0 µg/kg/body weight)

Locations

Country Name City State
Spain Hospital de la Santa Creu i Sant Pau Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Instituto de Salud Carlos III

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in oxytocin concentration Change in oxytocin concentration (pg/mL) after administration of 1.0 µg/kg/body weight of CRH or 0.9% sodium chloride (NaCl) Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection
Secondary Maximal change in oxytocin concentration (pg/mL) Maximal change in oxytocin concentration (pg/mL) after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl Within the two hours after the injection
Secondary Overall oxytocin secretion Oxytocin area under the curve after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl Within the two hours after the injection
Secondary Change in cortisol concentration (nmol/L) Change in cortisol concentration (nmol/L) after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection
Secondary Change in adrenocorticotropic hormone (ACTH) values Change in ACTH values (pmol/L) after administration of 1.0 µg/kg/body weight of CRH or 0.9% NaCl Baseline blood exam (timepoint 0) and further blood collections after 15, 30, 45, 60, 90 and 120 minutes after baseline blood collection
Secondary Mood assessment Correlation between Beck Depression Inventory-2 score (range from 0 to 63, higher scores mean a worse outcome) and baseline oxytocin concentration (pg/mL) Baseline
Secondary Quality of life assessment Correlation between 36 item- Short Form Health Survey score (range from 0 to 100, the higher scores indicate better health status) and baseline oxytocin concentration (pg/mL) Baseline
Secondary Impulsivity assessment Correlation between Barratt Impulsiveness Scale (range from 30 to 120, higher scores indicate greater impulsivity) and baseline oxytocin concentration (pg/mL) Baseline
Secondary Alexithymia assessment Correlation between Toronto Alexithymia scales-20 score (range from 20 to 100, higher scores mean a worse outcome) and baseline oxytocin concentration (pg/mL) Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT05831475 - LEAPTogether: An Intergenerational Intervention to Address Loneliness and Social Isolation N/A
Completed NCT03291717 - Bridging Community Gaps Photovoice N/A
Recruiting NCT06175299 - Social Functions to Promote Home-based Cognitive Training N/A
Completed NCT04573972 - Using Social Connectedness to Increase Physical Activity N/A
Not yet recruiting NCT05031247 - Refugee Mental Health and Wellness Pilot Study N/A
Completed NCT02596672 - Promoting Walking in Older Adults Living in Independent Living Communities in Northern Ireland: A Feasibility Study. N/A
Active, not recruiting NCT05678985 - Evaluating Impact and Implementation of Choose to Move (Phase 4) N/A
Active, not recruiting NCT04072185 - PHYSICAL ACTIVITY AS A MEASURE OF IMPROVING THE EMOTIONAL STATE AND SOCIALIZATION IN THE ELDERLY N/A
Completed NCT06018974 - Digital Gaming Intervention for Older People in Long-term Care N/A
Recruiting NCT04897802 - Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) Phase 4
Recruiting NCT06138301 - Telepsychiatry for Social Isolation in Youths N/A
Enrolling by invitation NCT06434298 - Provincial Scale-up of Choose to Move (CTM) Phase 4 N/A
Recruiting NCT05520450 - Telematic Support Group in Patients With Feelings of Loneliness and Social Isolation
Recruiting NCT05019053 - Acceptability/Feasibility of COVID-19 Intervention N/A
Completed NCT04281654 - Effects of Arts Engagement on Physical Performance, Cognition, Social Isolation, and Self-Perception in Older Adults N/A
Completed NCT04567940 - ENRED@TE. Social Support in Southern Spain. Interventional Study N/A
Completed NCT03472729 - AGE-ON 2.0: Expanding and Evaluating a Tablet Training Program for Older Adults N/A
Completed NCT03293823 - HARP-Project 1 Cognitive Training N/A
Completed NCT02835989 - Community Paramedicine at Home N/A
Completed NCT02041585 - Discharge Functional Status and Rehospitalization in the Elderly